Drugs / MRG-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03603431 | Apr 2018 → Mar 2019 | — | miRagen Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRG-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03603431 ↗ |
| Route | Other | “Intradermal injection of MRG-110 at two wound sites” NCT03603431 ↗ |